loading page

Immunophenotypic shifts during minimal residual evaluation in a case of leukemic form of Anaplastic large cell lymphoma ALK+
  • +7
  • Maria Clara Canellas,
  • Enrico Bruno-Riscarolli,
  • Cristiane Ferreira-Facio,
  • Daiana Lopes,
  • Vitor Botafogo,
  • Deborah Sutter,
  • Roberia de Pontes,
  • Marcelo Land,
  • Cristiane Milito,
  • Elaine Costa
Maria Clara Canellas
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira

Corresponding Author:[email protected]

Author Profile
Enrico Bruno-Riscarolli
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile
Cristiane Ferreira-Facio
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile
Daiana Lopes
Federal University of Rio de Janeiro
Author Profile
Vitor Botafogo
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile
Deborah Sutter
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile
Roberia de Pontes
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile
Marcelo Land
Federal University of Rio de Janeiro
Author Profile
Cristiane Milito
Universidade Federal do Rio de Janeiro
Author Profile
Elaine Costa
Federal University of Rio de Janeiro/Instituto de Pediatria e Puericultura Martagão Gesteira
Author Profile

Abstract

This study aims to describe immunophenotypic studies at diagnosis and follow up of a pediatric patient with leukemic phase of ALK+ anaplastic large cell lymphoma (ALCL) by multiparametric flow cytometry (MFC). An 8-color MFC combination of antibodies allowed to identify neoplastic cells in concentrations until 0.02% during minimal residual disease (MRD) monitoring. Immunophenotypic shifts occurred in key markers as CD30, CD7, CD2 and CD5, however neoplastic cells were clearly discriminated from normal populations. MFC can be a useful tool for ALCL diagnosis and MRD monitoring and may support therapeutic decisions.
Jul 2022Published in Cancer Reports volume 5 issue 7. 10.1002/cnr2.1526